The invention is directed to inhibition of p38-α kinase using compounds of formula (I) and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein Ar is an aryl group substituted with 0-5 non-interfering substituents, wherein two adjacent noninterfering substituents can form a fused aromatic or nonaromatic ring; L?1 and L2¿ are linkers; X is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X; n is 0-3; each R1 is hydrogen or a noninterfering substituent; (2) represents a single or double bond; one Z2 is CA or CR2A; the other Z?2 is CR3, CR3¿2, NR4 or N; and each R?2, R3 and R4¿ is independently hydrogen or a noninterfering substituent; Z?3 is NR5¿ or O; where R5 is hydrogen or a noninterfering substituent.